A Single Dose Pharmacokinetic Study of LY2140023 in Subjects With Hepatic Impairment.
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2013
At a glance
- Drugs Pomaglumetad methionil (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- 25 Oct 2012 Planned End Date changed from 1 Aug 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 29 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
- 04 Apr 2012 Planned end date changed from 1 May 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.